Leer en español →

Scientific deep-dive

GLP-1 Ileus & Bowel Obstruction: FDA Warning Evidence Review

FDA added ileus warnings to semaglutide and tirzepatide labels in 2023 after FAERS post-marketing reports. Absolute risk remains low; symptoms (severe abdominal pain, vomiting, no bowel movement) warrant immediate ER evaluation.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·11 citations

Frequently Asked Questions

Both semaglutide labels list ileus and intestinal obstruction in Section 6.2 (Postmarketing Experience), added in late 2023 after the FDA reviewed voluntary adverse-event reports. The Sodhi et al JAMA 2023 cohort study[1] found a hazard ratio of 4.22 (95% CI 1.02-17.40) for bowel obstruction in semaglutide/liraglutide users versus bupropion-naltrexone. A 121,254-patient Scandinavian cohort[2] and a 2025 Gastroenterology meta-analysis of 55 RCTs[3] did not replicate the elevated signal. The absolute risk is small but real — and the symptoms are unmistakable when they occur.
Ordinary GLP-1 nausea waxes and wanes around meals and improves between doses. Ileus presents as: severe and constant abdominal pain, abdominal distension (visibly swollen belly), inability to pass stool OR gas for more than 24 hours, persistent vomiting that does not resolve with antiemetics, and tympanic (drum-like) abdomen on percussion. Any of these is an ER trigger — do not wait it out.
Both Mounjaro and Zepbound labels list ileus in Section 6.2 (Postmarketing Experience). Published comparative pharmacoepidemiology with separate ileus rates for tirzepatide vs semaglutide is not yet available — most large-cohort studies pooled GLP-1 RAs. The mechanism (enteric-nervous-system motility suppression via GLP-1 receptors) applies to all GLP-1 RAs in principle.
Go to the ER (do not wait for the office) if you have any of: abdominal distension that you can see in the mirror, no stool or gas for more than 24 hours, persistent vomiting that prevents you from keeping anything down, severe constant abdominal pain (versus the colicky come-and-go pain of typical GLP-1 GI symptoms), fever, or tachycardia. Call your prescriber for: ordinary nausea waxing and waning around meals, constipation that responds to fiber and water, normal-pattern bowel movements that have just slowed.
Yes — stop the GLP-1 and seek emergency care. Once an ileus is confirmed and resolved, restarting is a clinical decision that depends on your specific case (prior abdominal surgery, opioid use, severity of the episode). Do not restart on your own. Use our switching and tapering guides only after talking to your prescriber.
Rare in absolute terms. Ileus and intestinal obstruction sit in the FDA Postmarketing Experience section precisely because they are reported voluntarily at a frequency too low to calculate from trials. The strongest signal, Sodhi et al JAMA 2023[1], found a hazard ratio of 4.22 (95% CI 1.02-17.40) versus bupropion-naltrexone — a relative increase on a small baseline — while a 121,254-patient Scandinavian cohort[2] (incidence about 1.3 per 1,000 patient-years) and a 2025 meta-analysis of 55 RCTs[3] found little or no excess. The honest summary: a small absolute risk, most visible in rapid-weight-loss populations, but with serious consequences when it does occur — which is why recognizing the symptoms matters more than the low base rate.
Risk reduction is clinician-led, not self-managed. Measures your prescriber may discuss include gradual dose titration rather than fast escalation, staying well hydrated, keeping bowel movements regular with adequate fiber and fluids, and treating ordinary constipation early before it stalls. Most important is telling your clinician up front about factors that amplify the underlying gut-slowing mechanism — prior abdominal surgery with adhesions, opioid use, prior radiation, or severe baseline constipation. None of these has a published adjusted hazard ratio in the GLP-1 literature yet, so the adjustment is clinical judgment. Do not treat a suspected obstruction with more laxatives at home: if stool and gas stop for more than 24 hours, that is an ER visit, not a fiber problem.
For most people, no. The underlying effect is functional — GLP-1 receptor agonists slow gut motility[4][5], and when that tips into an ileus it typically resolves once the drug is stopped and the obstruction is treated with bowel rest, IV fluids, and sometimes NG-tube decompression. The real danger is a missed or delayed obstruction: a small-bowel obstruction that progresses to strangulation or perforation can cause permanent damage and, rarely, death — which is the whole reason the ER-level red flags (visible distension, no stool or gas for over 24 hours, persistent vomiting, severe constant pain) are non-negotiable. There is no evidence that ordinary GLP-1 slowing permanently injures a healthy bowel.
That is a decision for your prescriber, not a self-assessment. Prior abdominal surgery with adhesions, prior radiation enteritis, a history of bowel obstruction, opioid use, and severe baseline constipation are all mechanistically plausible amplifiers of the motility slowing that GLP-1 drugs cause[4] — but none has a published adjusted hazard ratio in the GLP-1 literature yet, so there is no formula. Societies including the American Society of Anesthesiologists have issued consensus guidance reflecting that plausibility. If any of these apply to you, raise them explicitly before starting or escalating, and agree on a clear plan for which symptoms send you to the ER.

In late 2023, the FDA added “ileus” and “intestinal obstruction” to the postmarketing experience section of every GLP-1 receptor agonist label — Ozempic [8], Wegovy [7], Zepbound [9], Mounjaro [10], Saxenda [11], and later Foundayo [11]. The published evidence on the magnitude of the signal is genuinely mixed: Sodhi et al JAMA 2023[1] reported a hazard ratio of 4.22 (95% CI 1.02-17.40) for bowel obstruction in a US weight-loss cohort [1], while a 121,254-patient Scandinavian cohort[2] and a 2025 Gastroenterology meta-analysis of 55 RCTs[3] did not replicate the elevated signal. The absolute risk is small either way — but the consequences of a missed ileus include emergency surgery, NG-tube decompression, and rare death. This article walks through the verbatim FDA label language, all three published datasets, the enteric-nervous-system mechanism, and the symptom profile that distinguishes ileus from ordinary GLP-1 nausea so the ER-level red flags are unmistakable.

The verbatim FDA label language

The labels are nearly identical across the GLP-1 class. All six FDA-approved drugs list ileus and intestinal obstruction in Section 6.2 (Postmarketing Experience), pulled 2026-05-07 directly from the DailyMed-hosted prescribing information for each:

DrugLabel sectionVerbatim language
Wegovy [7]6.2acute pancreatitis and necrotizing pancreatitis, sometimes resulting in death; ileus, intestinal obstruction, severe constipation including fecal impaction
Ozempic [8]6.2ileus, intestinal obstruction, severe constipation including fecal impaction
Zepbound [9]6.2acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction
Mounjaro [10]6.2acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction
Saxenda [11]6.2acute pancreatitis; hemorrhagic and necrotizing pancreatitis, sometimes resulting in death; ileus, intestinal obstruction, severe constipation including fecal impaction
Foundayo [11]6.2acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death; ileus, intestinal obstruction, severe constipation including fecal impaction

The Postmarketing Experience section — distinct from the Adverse Reactions section that summarizes clinical-trial rates — is FDA shorthand for “reported voluntarily from a population of uncertain size, so we cannot calculate a frequency.” That is exactly why the labels do not provide a percentage and exactly why the JAMA cohort study below matters.

Sodhi et al, JAMA 2023 — the strongest signal

The Sodhi et al letter in JAMA 2023[1] is the single most-cited pharmacoepidemiology paper on GLP-1 and gastrointestinal adverse events in the weight-loss population [1]. The study used the PharMetrics Plus commercial-claims database (2006-2020) and compared semaglutide and liraglutide users to bupropion-naltrexone users — all three indicated for weight loss. n=5,411 total. Hazard ratios for prespecified outcomes:

  • Bowel obstruction: HR 4.22 (95% CI 1.02-17.40) — statistically significant.
  • Pancreatitis: HR 9.09 (95% CI 1.25-66.00) — statistically significant, very wide CI reflecting small event count.
  • Gastroparesis: HR 3.67 (95% CI 1.15-11.90) — statistically significant.
  • Biliary disease: HR 1.50 (95% CI 0.89-2.53) — not statistically significant in this dataset (the broader gallbladder evidence including bariatric-surgery rapid-loss data is in our companion GLP-1 + gallbladder article ).

The wide confidence intervals — particularly for pancreatitis (1.25-66.00) — are the result of small absolute event numbers in a cohort of 5,411. The point estimate matters; the precision is genuinely limited. Sodhi et al stated this directly in the letter conclusion: “Use of GLP-1 agonists for weight loss compared with use of bupropion-naltrexone was associated with increased risk of pancreatitis, gastroparesis, and bowel obstruction but not biliary disease.” That sentence, plus the coincident timing of the FDA postmarketing label addition (September 2023), is what made this letter clinically load-bearing despite its size. The gastroparesis (“stomach paralysis”) half of that signal — what it means, and why the headlines overstate it — is covered in does Ozempic cause stomach paralysis?

The Scandinavian counter-finding

A much larger Scandinavian cohort study published the following year in Clinical Gastroenterology and Hepatology[2] compared 121,254 GLP-1 receptor agonist users to 185,027 SGLT2 inhibitor users across Sweden, Denmark, and Norway from 2013 to 2021 [2]. The finding for intestinal obstruction:

  • GLP-1 RA vs SGLT2i: HR 0.83 (95% CI 0.69-1.01) — not statistically elevated.
  • Incidence rate: 1.3 per 1,000 patient-years (GLP-1 RA) vs 1.6 per 1,000 patient-years (SGLT2i).

Three differences plausibly explain the gap from Sodhi's finding: the Scandinavian cohort was mostly type 2 diabetes patients (not weight-loss patients with higher BMI and faster loss); the comparator was a different diabetes drug class (SGLT2i, not bupropion-naltrexone); and the Scandinavian sample was 22-fold larger, giving tighter confidence intervals. Either way, the Scandinavian dataset does not support a clinically meaningful excess of ileus on a GLP-1 background.

The 2025 RCT meta-analysis

A 2025 Gastroenterology systematic review and meta-analysis of 55 randomized controlled trials including 106,395 participants[3] examined GLP-1-associated gastrointestinal adverse events comprehensively [3]. For intestinal obstruction and paralytic ileus, the conclusion was that GLP-1 RAs “probably have little or no effect” on the risk versus placebo. The same meta-analysis confirmed elevated risks for cholelithiasis (RR 1.46, 95% CI 1.09-1.97) and for gastroesophageal reflux disease (RR 2.19, 95% CI 1.48-3.25) — so it is not the case that the meta-analysis simply failed to find any signal.

RCTs systematically under-detect rare events because they enroll healthier subjects, exclude patients with prior abdominal surgery or other ileus risk factors, and are shorter in duration than real-world cohorts. That makes the RCT meta-analysis well-powered for common GI symptoms but underpowered for ileus specifically.

Magnitude comparison

Intestinal obstruction risk on GLP-1 receptor agonists across the three load-bearing datasets. Hazard ratios and risk ratios versus each study's comparator (bupropion-naltrexone, SGLT2 inhibitors, or placebo). HR/RR of 1.0 = no excess risk; values above 1.0 indicate elevated risk.[1][2][3]

  • Sodhi et al, JAMA 2023 — US weight-loss cohort (n=5,411) vs bupropion-naltrexone4.22 HR
    95% CI 1.02-17.40 — statistically significant; wide CI from small event count
  • Ueda et al, Scandinavian cohort 2024 (n=121,254) vs SGLT2 inhibitors0.83 HR
    95% CI 0.69-1.01 — not statistically elevated; mostly T2D population
  • 2025 Gastroenterology meta-analysis — 55 RCTs (n=106,395) vs placebo1 RR (approx)
    \
Intestinal obstruction risk on GLP-1 receptor agonists across the three load-bearing datasets. Hazard ratios and risk ratios versus each study's comparator (bupropion-naltrexone, SGLT2 inhibitors, or placebo). HR/RR of 1.0 = no excess risk; values above 1.0 indicate elevated risk.

Why the studies disagree

The three datasets are not as contradictory as they look on first read. Sodhi captured a US weight-loss-only commercial population with relatively rapid loss and a comparator (bupropion-naltrexone) that is less GI-active than the comparators in the other studies. The Scandinavian study captured a mostly-T2D population with slower titration, less weight loss, and an SGLT2i comparator that itself has no ileus signal. The RCT meta-analysis pooled trials with protocol-driven titration and pre-screened patients. The most coherent reading of all three together: a small absolute excess risk that is most visible in the rapid-weight-loss US weight-management context and washes out in the broader T2D and trial populations.

The mechanism — GLP-1 receptors in enteric neurons

Two mechanism papers are load-bearing. Schirra et al[4] documented that physiologic GLP-1 doses suppress the migrating motor complex (MMC) in the human jejunum, reducing the median fasting MMC count and motility index. Amato et al[5] characterized the peripheral motor action of GLP-1 through enteric neuronal receptors and showed that GLP-1 inhibits small-intestine motility via presynaptic GLP-1 receptors on enteric neurons, modulating nitric-oxide release and decreasing cholinergic neurotransmission.

The clinical consequence: GLP-1 receptor agonists slow the whole gut, not just gastric emptying. In a patient with good baseline motility, that produces ordinary GLP-1 symptoms (early satiety, mild constipation, occasional nausea). In a patient with predisposing factors — adhesions from prior abdominal surgery, opioid co-administration, narrowed bowel from prior radiation, baseline severe constipation — the same motility suppression can tip the bowel into an actual ileus. None of these risk modifiers has a published adjusted hazard ratio in the GLP-1 literature yet, so any patient with these conditions should discuss them with the prescribing clinician.

How to tell ileus from ordinary GLP-1 GI symptoms

The single most useful clinical skill for a GLP-1 patient is the ability to distinguish typical post-injection nausea from the signs of actual ileus. The contrast is sharp once you know what to look for:

FeatureOrdinary GLP-1 GI symptomsIleus / bowel obstruction
Pain patternMild, comes and goes around mealsSevere, constant, often diffuse and worsening
Abdominal distensionNone or mild “fullness”Visible swelling — the belly looks bigger
Stool / gas passageSlowed but presentAbsent for >24 hours
VomitingEases between meals; antiemetics helpPersistent; unresponsive to antiemetics
Sound on percussionNormalTympanic (drum-like) over distended bowel
Heart rate / blood pressureNormal or mildly elevatedTachycardia, sometimes hypotension
FeverAbsentMay develop with strangulation or perforation

Any one of the right-column items is an ER trigger. Two or more, especially distension plus absent flatus, is an emergency-room presentation. Do not call your prescriber first — go directly. Acute small-bowel obstruction progressing to strangulation or perforation can become irreversible within hours.

What to do if you suspect ileus

  1. Stop the GLP-1. Do not take your next weekly injection if you have ileus symptoms. The drug is worsening the picture.
  2. Stop oral intake of food and fluids. Do not try to push solids or liquids through. Continued intake into an obstructed bowel is dangerous.
  3. Go to the emergency department. Call 911 if pain is severe or you are vomiting blood or coffee-ground material.
  4. Tell the ED team you are on a GLP-1 receptor agonist. Name the specific drug. They will need this for both the differential diagnosis and any imaging or surgical planning. The American Society of Anesthesiologists has formal guidance on perioperative GLP-1 management — see our GLP-1 + surgery and anesthesia article .
  5. Bring your medication list. Opioid analgesics worsen ileus; the ED needs to know what else you are on.

Risk factors and the not-yet-quantified questions

The published pharmacoepidemiology has not yet quantified adjusted hazard ratios for the most clinically obvious ileus risk modifiers in a GLP-1 context. Specifically: prior abdominal surgery with adhesions, opioid co-administration, prior radiation enteritis, severe baseline constipation, and aggressive titration speed are all mechanistically plausible risk amplifiers, and societies including the American Society of Anesthesiologists and the American Society for Parenteral and Enteral Nutrition have published consensus guidance reflecting that plausibility, but no peer-reviewed cohort study has published adjusted HRs by risk modifier. If you have any of these conditions and you are starting a GLP-1, raise them with your prescriber explicitly — the clinical-judgment adjustment is real even if the formal adjusted estimate is not yet on PubMed.

The bottom line

  • Every FDA-approved GLP-1 label lists ileus and intestinal obstruction in Section 6.2 (Postmarketing Experience), added in 2023.
  • Sodhi et al JAMA 2023[1] reported HR 4.22 (95% CI 1.02-17.40) for bowel obstruction in a US weight-loss cohort — the strongest single signal.
  • Ueda et al Scandinavian cohort 2024[2] found HR 0.83 — not significant.
  • 2025 Gastroenterology meta-analysis of 55 RCTs[3] found “little or no effect” on intestinal obstruction.
  • Best reading: small absolute excess risk most visible in the rapid-weight-loss US weight-management context; washes out in broader populations.
  • The clinically actionable skill is recognizing the symptom profile — distension, no stool/gas for >24h, severe constant pain, persistent vomiting — and going to the ER, not the prescriber, when those appear.

Further reading

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

References

  1. 1.Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023. PMID: 37796527.
  2. 2.Ueda P, Wintzell V, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study. Clin Gastroenterol Hepatol. 2024. PMID: 37716613.
  3. 3.Multinational systematic review and meta-analysis collaborative. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025. PMID: 40499738.
  4. 4.Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 2008. PMID: 18298441.
  5. 5.Amato A, Cinci L, Rotondo A, Serio R, Faussone-Pellegrini MS, Vannucchi MG, Mulè F. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil. 2010. PMID: 20158614.
  6. 6.Real-world pharmacovigilance authors (FAERS analysis). Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database. Diagnostics. 2024. PMID: 39767190.
  7. 7.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 6.2 Postmarketing Experience: Gastrointestinal Disorders (revised March 19, 2026). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  8. 8.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, Section 6.2 Postmarketing Experience: Gastrointestinal (revised October 14, 2025). FDA Approved Labeling — DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  9. 9.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 6.2 Postmarketing Experience: Gastrointestinal (revised April 22, 2026). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  10. 10.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information, Section 6.2 Postmarketing Experience: Gastrointestinal (revised April 22, 2026). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  11. 11.Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information, Section 6.2 Postmarketing Experience: Gastrointestinal (revised February 25, 2026); and Eli Lilly and Company, FOUNDAYO (orforglipron) tablets — Section 6.2 Postmarketing Experience: Gastrointestinal Disorders (revised April 1, 2026). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143

Related research

GLP-1 Medications and Gallbladder Disease: What the STEP, SURMOUNT, and FDA Label Data Actually Show

Cholelithiasis on Wegovy ran 1.6% vs 0.7% placebo (Section 5.3), Zepbound 1.1% vs 1% (Section 5.4), Saxenda 2.2% vs 0.8% (Section 5.3). The 2022 JAMA Internal Medicine meta-analysis of 76 trials and 103,371 patients pooled the GLP-1 risk at RR 1.37 (95% CI 1.23-1.52). Here is the verbatim FDA label data, the trial percentages from STEP-1 (PMID 33567185) and SURMOUNT-1 (PMID 35658024), and what the rapid-weight-loss mechanism literature says about the absolute risk.

12 min read

Ashwagandha and GLP-1: Cortisol, Stress Eating, and Combined Use Evidence

No pharmacokinetic drug interaction is listed in the FDA Section 7 labels for Wegovy (ee06186f), Ozempic (adec4fd2), Zepbound (487cd7e7), or Mounjaro (d2d7da5d). The clinical concerns are different: (1) NIH LiverTox assigns ashwagandha Likelihood Score B — 'likely cause of clinically apparent liver injury' — with fatal cases in pre-existing liver disease; (2) Sharma 2018 (PMID 28829155) found significant TSH reduction and T3/T4 elevation in subclinical hypothyroid patients — relevant for anyone on levothyroxine + GLP-1; (3) three RCTs (Chandrasekhar 2012 PMID 23439798, Lopresti 2019 PMID 31517876, Salve 2019 PMID 32021735) confirm modest cortisol reduction — a complementary mechanism to GLP-1 appetite suppression but not additive weight loss; (4) Choudhary 2017 (PMID 27055824) found modest weight/BMI reduction in chronically stressed adults — stress-mediated, not a direct anti-obesity effect; (5) Langade 2019 (PMID 31728244) confirmed sedative properties (somnifera means sleep-inducing) that can compound GLP-1 fatigue; (6) pregnancy contraindicated. NIH ODS fact sheet verbatim. Philips 2023 case series (PMID 37756041): 3 of 8 single-ingredient HILI patients with pre-existing liver disease died. Verified 2026-05-10.

18 min read

Stopping Wegovy / Zepbound / Ozempic: Rebound Weight Gain Evidence and Transition Planning

Three randomized trials — STEP-4 (Rubino JAMA 2021, PMID 33755728), the STEP-1 extension (Wilding Diabetes Obes Metab 2022, PMID 35441470), and SURMOUNT-4 (Aronne JAMA 2024, PMID 38078870) — measured what happens when GLP-1 therapy is stopped. Semaglutide: 6.9 pp regain over 48 weeks (STEP-4); ~67% of weight lost reversed within 1 year (STEP-1 extension). Tirzepatide: 14.0 pp regain over 52 weeks; only 16.6% of patients who stopped maintained ≥80% of lead-in loss (SURMOUNT-4). Covers the mechanism (appetite returns before weight does), taper evidence (none), maintenance dosing options, cost stopping, pregnancy washout (Wegovy label: 2 months), side-effect stopping, and prescriber talking points.

18 min read

Compounded Semaglutide Bioequivalence: What 503A Pharmacies Actually Have to Test

Compounded semaglutide isn't FDA-approved, but that doesn't mean it's untested. A close look at what 503A and 503B pharmacies are actually required to verify, and where the real quality risks live.

11 min read

Compounded Semaglutide vs Wegovy: Bioequivalence Evidence Review

No FDA bioequivalence study exists between compounded semaglutide and Wegovy. The 2022-2025 shortage carveout closed February 21, 2025, and the FDA is now issuing warning letters to online sellers. What the rules actually say.

10 min read

Foundayo vs Wegovy: Head-to-Head Evidence Comparison

Foundayo (orforglipron) is an oral small-molecule GLP-1 tablet; Wegovy (semaglutide) is a once-weekly injection. ATTAIN-1 labeled-dose ~11.1% TBWL vs STEP-1 Wegovy ~14.9%. Trial data, side effects, CV evidence, form factor, and a decision framework.

14 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

8.0

ShedRx

Mainstream telehealth GLP-1 access

Pricing Compare

Get started →
Read full review →
7.2

Fella Health

Men's weight loss

Pricing Compare

Get started →
Read full review →
7.6

SkinnyRx

Mainstream telehealth GLP-1 access

Pricing Compare

Get started →
Read full review →
Compare all 564 vetted providers →Browse the full directory